Five-year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia

Bojang, K; Milligan, P; Pinder, M; Doherty, T; Leach, A; Ofori-Anyinam, O; Lievens, M; Kester, K; Schaecher, K; Ballou, WR; +1 more... Cohen, J; (2009) Five-year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia. Human vaccines, 5 (4). pp. 242-247. ISSN 1554-8600 https://researchonline.lshtm.ac.uk/id/eprint/5143

Permanent Identifier

Use this permanent URL when citing or linking to this resource.

https://researchonline.lshtm.ac.uk/id/eprint/5143

Abstract

Share

Download

Full text not available from this repository.

Downloads

View details

Google Scholar